ArticleHuman reproduction open2026
Perfluorooctane sulfonate (PFOS) in follicular fluid and human granulosa cell dysfunction: a physiologically based toxicokinetic model translation of long-term low-level
Article in Human reproduction open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
study questionAre bioactive human-equivalent doses (HEDs) of perfluorooctane sulfonate (PFOS), derived from long-term low-level SUMMARY ANSWER: The bioactive HEDs overlapped with and, in some cases, were lower than the median HEDs inferred from follicular fluid PFOS concentrations. WHAT IS KNOWN ALREADY: PFOS exposure is a growing public health concern, with evidence suggesting adverse female reproductive effects. However, the relevance of current human exposure levels to granulosa cell function remains unclear. STUDY DESIGN SIZE DURATION: Four independent vials of human granulosa cells (HGrC1 cells) were thawed and expanded into separate flasks (biological replicates). Cells were allocated to four experimental groups and exposed to PFOS (0.01, 0.1, or 1 µM) or vehicle control (0.05% DMSO) for up to 12 weeks, with re-dosing at each passage. Different apical endpoints, along with transcriptomic changes, were evaluated at designated time points. Clinical relevance of PFOS risk to human granulosa cells was assessed by integrating experimental data with physiologically based toxicokinetic (PBTK) modeling. PARTICIPANTS/MATERIALS SETTING
methodsViability of HGrC1 cells was assessed using the Alamar Blue assay. Estradiol and progesterone secretion were quantified by enzyme-linked immunosorbent assay. Flow cytometry was used to determine the proportions of live, apoptotic and necrotic cells, as well as cell cycle distribution. Global mRNA expression was assessed by DNA nanoball sequencing technology (DNBSEQ), whereas pathway-level molecular functions were derived using bioinformatic tools. Benchmark concentrations (BMCs) were calculated from key endpoints with concentration-dependent responses and used to estimate HEDs via PBTK modeling. These HEDs were compared with HEDs inferred from follicular fluid PFOS levels reported in the literature to derive bioactivity exposure ratios (BERs) and assess relevance to human exposure. MAIN RESULTS AND THE ROLE OF CHANCE: In HGrC1 cells, long-term PFOS exposure altered steroidogenesis, apoptosis/necrosis, cell cycle distribution ( LARGE SCALE DATA: Raw and processed RNA-sequencing data are deposited in NCBI Gene Expression Omnibus (GEO) under accession number GSE315651. LIMITATIONS REASONS FOR CAUTION: The estimated exposure values were based on predictions from a PBTK model rather than empirical human exposure data. Also, differences in protein concentrations WIDER IMPLICATIONS OF THE
findingsOur findings suggest that PFOS concentrations in follicular fluid from women undergoing ART and those who have been occupationally exposed may be sufficient to perturb granulosa cell mRNA expression and key pathways, including eicosanoid, interleukin, and GPCR signaling. The identified genes may serve as candidate biomarkers linking PFOS exposure to clinical outcomes in ART settings. Overall, this study provides a framework for interpreting PFOS reproductive toxicity and refining health-protective exposure thresholds. STUDY FUNDING/COMPETING INTERESTS: This research was supported by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (Faculty of Sciences, Novi Sad: Grants No. 451-03-137/2025-03/200125 & 451-03-136/2025-03/200125), the Institute of Physics, Belgrade, National Institute of the Republic of Serbia, and the Science Fund of the Republic of Serbia, Grant No. 7010, 'Integration of Biological Responses and PBTK Modeling in Chemical Toxicity Assessment: А Case Study of Perfluorooctanoic Acid (PFOA)-ToxIN'. The authors declare no conflicts of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.